Results 11 to 20 of about 5,515 (141)
The Evolving Role of Ivabradine for Focal Atrial Tachycardia: A Systematic Review. [PDF]
J ArrhythmOverview of the evolving role of ivabradine in focal atrial tachycardia (FAT), highlighting its HCN‐mediated mechanism, features of ivabradine‐sensitive FAT, hypothesized predictors of response, special populations requiring special considerations, and potential adverse effects.
Balweel H +5 more
europepmc +2 more sources
The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels
Frontiers in Pharmacology, 2022 Background and purpose: Ivabradine is clinically administered to lower the heart rate, proposedly by inhibiting hyperpolarization-activated cyclic nucleotide-gated cation channels in the sinoatrial node. Recent evidence suggests that voltage-gated sodium
Benjamin Hackl +16 more
doaj +1 more source
International Journal of Cardiology: Heart & Vasculature, 2021 Objectives: We assessed left ventricular (LV) function and central hemodynamic effects in patients with a heart rate (HR) at rest of ≥70 beats per minute (bpm) and chronic coronary syndrome (CCS) after long-term treatment with ivabradine compared to ...
Anna Lena Hohneck +8 more
doaj +1 more source
Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. [PDF]
PLoS ONE, 2012 BACKGROUND: Elevated heart rate is associated with increased cardiovascular morbidity. The selective I(f) current inhibitor ivabradine reduces heart rate without affecting cardiac contractility, and has been shown to be cardioprotective in the failing ...
Li Yue-Chun +6 more
doaj +1 more source
ESC Heart Failure, 2021 Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medications.
Ying‐Hsiang Lee +9 more
doaj +1 more source
Cardiology and Therapy, 2020 Introduction Dosing frequency is an important factor influencing medication compliance in patients with heart failure (HF), which in turn is imperative in achieving the desired therapeutic outcome.
Ajit Mullasari +1 more
doaj +1 more source
Indian Heart Journal, 2023 Objectives: Ivabradine may have a role in rate control of atrial fibrillation (AF) due to effects on HCN channels in AV node. We studied role of Ivabradine in rate control of rheumatic AF. Methods: 80 patients, rheumatic AF, HR > 100 bpm (age 47 ± 11 yrs,
Arpita Katheria +8 more
doaj +1 more source
Ivabradine Reduces Chemokine-Induced CD4-Positive Lymphocyte Migration
Mediators of Inflammation, 2010 Aims. Migration of CD4-positive lymphocytes into the vessel wall is a critical step in atherogenesis. Recent data suggest that ivabradine, a selective I(f)-channel blocker, reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice ...
Thomas Walcher +6 more
doaj +1 more source
ESC Heart Failure, 2021 Aims Ivabradine has been used in patients who have chronic heart failure (HF) with reduced ejection fraction (HFrEF) and concomitant sinus heart rate ≥70 bpm. This administration for acute HFrEF remains a concern. This study used a real‐world multicentre
Chia‐Te Liao +9 more
doaj +1 more source
Frontiers in Pediatrics, 2020 We report on a 12-month-old girl with an ectopic atrial tachycardia successfully treated with the combination of a beta blocking agent and Ivabradine that acts on cardiac pacemaker cells by selectively inhibiting the If channel.
Holger Michel +4 more
doaj +1 more source